Why the study?
Data comparing the efficacy and safety of ticagrelor versus prasugrel in women and men with acute coronary syndromes planned for an invasive strategy were limited.
Does ticagrelor compared to prasugrel improve clinical outcomes in women and men with acute coronary syndrome planned for an invasive strategy?
Does ticagrelor compared to prasugrel improve clinical outcomes in women and men with acute coronary syndrome planned for an invasive strategy?
Sex should not dictate P2Y12 choice in invasive ACS; extends ISAR-REACT 5 superiority without significant sex interaction.
AIM: inhibitors are limited. This study was conducted to assess the efficacy and safety of ticagrelor versus prasugrel in women and men with acute coronary syndromes (ACS) planned for an invasive strategy. METHODS: This pre-specified analysis of the ISAR-REACT 5 trial included 956 women and 3,062 men with ACS randomly assigned to either ticagrelor or prasugrel. The primary endpoint was the 12-month incidence of death, myocardial infarction, or stroke; the safety endpoint was the 12-month incidence of bleeding (type 3-5 according to the Bleeding Academic Research Consortium [BARC]). RESULTS: =0.571). CONCLUSIONS: Although there was no significant interaction between sex and treatment effect of study drugs, the superior efficacy of prasugrel was more evident among men. No difference in bleeding between the two study groups was seen for both women and men.
No takes yet. Share an insight, caveat, or question.
Gewalt et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: